Ney Carter Borges: Coronary Intravascular Lithotripsy – Clinical Performance and Safety
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“Coronary Intravascular Lithotripsy (IVL): Clinical Performance and Safety
Coronary intravascular lithotripsy (IVL) is an established plaque-modification technique designed to facilitate optimal stent expansion in moderately to severely calcified coronary lesions. By delivering localized acoustic pressure waves through a low-pressure balloon system, IVL induces controlled microfractures in both superficial and deep calcium, improving vessel compliance while minimizing vascular trauma.
Clinical evidence from the Disrupt CAD I–IV trials demonstrates a procedural success rate of approximately 92%, defined by successful stent delivery with residual stenosis below target thresholds and absence of in-hospital major adverse cardiac events. In these studies, residual stenosis <50% was achieved in approximately 95% of treated lesions, reflecting effective calcium modification and favorable acute luminal gain.
Importantly, IVL is associated with a low incidence of serious complications, including a coronary perforation rate below 1%, which is substantially lower than that reported with some atherectomy-based strategies. This safety profile, combined with technical simplicity and a short learning curve, supports IVL as a valuable option for contemporary percutaneous coronary intervention in calcified coronary artery disease.”
Title: Shocking the Rock With Coronary Intravascular Lithotripsy in Contemporary Practice
Authors: Debabrata Dash, Anna Emily Bortnic
Read the Full Article on American College of Cardiology
Stay updated with Hemostasis Today.
-
Jul 7, 2026, 23:20Balaji Balagani: Exploring Pulmonary Embolism
-
Jul 7, 2026, 23:03Roxana González Mazarío: The Phenotype-Specific Cardiovascular Risks in AAV
-
Jul 7, 2026, 22:52Harry Spoelstra: LongC0VID Still has Zero Proven Treatments
-
Jul 7, 2026, 22:39Satya K. Morar: Acute Portal Vein Thrombosis as an Exceptionally Rare Complication of Liver Biopsy in CVID
-
Jul 7, 2026, 22:23Aravind Palraj: Antiphospholipid Syndrome is not Just ‘Start Warfarin and Follow INR’
-
Jul 7, 2026, 20:59William Aird: An Unlucky Turn Into the Renal Artery
-
Jul 7, 2026, 20:58Chokri Ben Lamine: The Two-Hit Model of TRALI
-
Jul 7, 2026, 20:57New Issue of Blood Out Now – Blood Journals Portfolio
-
Jul 7, 2026, 20:56Priyadarshini Ramakrishnan: Schistocytes – The Most “Misleading Heroes” in a Peripheral Smear